Literature DB >> 22235994

Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction.

P Bachireddy1, K Rakhra, D W Felsher.   

Abstract

Despite complex genomic and epigenetic abnormalities, many cancers are irrevocably dependent on an initiating oncogenic lesion whose restoration to a normal physiological activation can elicit a dramatic and sudden reversal of their neoplastic properties. This phenomenon of the reversal of tumorigenesis has been described as oncogene addiction. Oncogene addiction had been thought to occur largely through tumour cell-autonomous mechanisms such as proliferative arrest, apoptosis, differentiation and cellular senescence. However, the immune system plays an integral role in almost every aspect of tumorigenesis, including tumour initiation, prevention and progression as well as the response to therapeutics. Here we highlight more recent evidence suggesting that oncogene addiction may be integrally dependent upon host immune-mediated mechanisms, including specific immune effectors and cytokines that regulate tumour cell senescence and tumour-associated angiogenesis. Hence, the host immune system is essential to oncogene addiction.
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22235994      PMCID: PMC3278684          DOI: 10.1111/j.1365-2249.2011.04514.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  86 in total

Review 1.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 2.  The tumour microenvironment as a target for chemoprevention.

Authors:  Adriana Albini; Michael B Sporn
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

3.  Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence.

Authors:  Maurice Reimann; Soyoung Lee; Christoph Loddenkemper; Jan R Dörr; Vedrana Tabor; Peter Aichele; Harald Stein; Bernd Dörken; Thomas Jenuwein; Clemens A Schmitt
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

Review 4.  AIDS-related malignancies.

Authors:  Chris Boshoff; Robin Weiss
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

5.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

6.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

7.  Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma.

Authors:  Michael Girardi; David Oppenheim; Earl J Glusac; Renata Filler; Allan Balmain; Robert E Tigelaar; Adrian C Hayday
Journal:  J Invest Dermatol       Date:  2004-03       Impact factor: 8.551

8.  Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Authors:  Claudia Wrzesinski; Chrystal M Paulos; Andrew Kaiser; Pawel Muranski; Douglas C Palmer; Luca Gattinoni; Zhiya Yu; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

Review 9.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

Review 10.  Targeted cancer therapy.

Authors:  Charles Sawyers
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

View more
  15 in total

Review 1.  Kidney transplantation and the ageing immune system.

Authors:  Dianne McKay; Julie Jameson
Journal:  Nat Rev Nephrol       Date:  2012-11-13       Impact factor: 28.314

2.  Broadening the translational immunology landscape.

Authors:  M Peakman
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

3.  Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model.

Authors:  Charles H Lineweaver; Paul C W Davies; Mark D Vincent
Journal:  Bioessays       Date:  2014-07-14       Impact factor: 4.345

Review 4.  MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.

Authors:  E Hessmann; G Schneider; V Ellenrieder; J T Siveke
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

5.  Elevated neutrophil elastase and acrolein-protein adducts are associated with W256 regression.

Authors:  M Jaganjac; M Poljak-Blazi; R J Schaur; K Zarkovic; S Borovic; A Cipak; M Cindric; K Uchida; G Waeg; N Zarkovic
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

Review 6.  SGF29 and Sry pathway in hepatocarcinogenesis.

Authors:  Nobuya Kurabe; Shigekazu Murakami; Fumio Tashiro
Journal:  World J Biol Chem       Date:  2015-08-26

Review 7.  MYC activation is a hallmark of cancer initiation and maintenance.

Authors:  Meital Gabay; Yulin Li; Dean W Felsher
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

Review 8.  Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.

Authors:  Alice C Fan; Jennifer J O'Rourke; Dave R Praharaj; Dean W Felsher
Journal:  Expert Opin Investig Drugs       Date:  2013-08-12       Impact factor: 6.206

Review 9.  Noncanonical roles of the immune system in eliciting oncogene addiction.

Authors:  Stephanie C Casey; David I Bellovin; Dean W Felsher
Journal:  Curr Opin Immunol       Date:  2013-04-06       Impact factor: 7.486

Review 10.  Inactivation of MYC reverses tumorigenesis.

Authors:  Y Li; S C Casey; D W Felsher
Journal:  J Intern Med       Date:  2014-07       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.